gefitinib has been researched along with emd1214063 in 3 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (emd1214063) | Trials (emd1214063) | Recent Studies (post-2010) (emd1214063) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 76 | 11 | 73 |
Protein | Taxonomy | gefitinib (IC50) | emd1214063 (IC50) |
---|---|---|---|
Hepatocyte growth factor receptor | Homo sapiens (human) | 0.0048 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Bruns, R; Chen, YM; Cheng, Y; Chian, CF; Johne, A; Kim, DW; Kim, SW; Liu, X; Lu, S; Pan, H; Park, K; Scheele, J; Soo, RA; Straub, J; Tan, DSW; Wu, YL; Yang, JC; Zhang, Y; Zhao, J; Zhou, J | 1 |
Ahmad, AR; Berghoff, K; Bruns, R; Cheng, Y; Hsia, TC; Johne, A; Kim, DW; Liam, CK; Lu, S; Shin, SW; Soo, RA; Wu, YL; Yang, JC; Zhang, Y; Zhao, J; Zhou, J | 1 |
2 trial(s) available for gefitinib and emd1214063
Article | Year |
---|---|
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-met; Pyridazines; Pyrimidines; Risk Assessment; Survival Analysis; Treatment Outcome | 2020 |
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors | 2023 |
1 other study(ies) available for gefitinib and emd1214063
Article | Year |
---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |